Gene fusions are vital biomarkers for tumor diagnosis and drug development, with precise detection becoming increasingly ...

Targeted testing for gene fusions of interest at the DNA or RNA level is currently in clinical use as it has diagnostic, prognostic, and therapeutic significance. Lead investigator Jonathan ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

The addiction of cancer cells to causal gene fusions often results in amplification, in vivo, which can be exploited to reveal unidentified recurrent gene rearrangements. Based on this observation, we ...

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...

(MENAFN- JCN NewsWire) Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

The multifaceted functions of P450 genes in chemical modification of prenyl indole alkaloids and thermophilic fungal adaption to cold stress. News organizations may use or redistribute this image ...

We have investigated the prediction of protein interactions through the analysis of domain fusion to assess whether metabolic enzymes have a higher participation in gene-fusion events compared ...